title: [Novel targeted drug therapies in breast cancer].
abstract: Tamoxifen, an effective and very well tolerated drug, binding specifically to the estrogen receptor, was approved for the treatment of breast cancer already more than 30 years ago, and can already be considered as a targeted drug. Targeted drugs, however, frequently refer to novel drugs directed at specific molecular structures in a predetermined manner. Trastuzumab was approved for the treatment of metastatic breast cancer in 1998. Since then, lapatinib and bevasizumab have been approved for the treatment of breast cancer. This review deals with treatment results obtained with targeted breast cancer drugs, use of these drugs and future prospects of such therapies.
authors.affiliation: HYKS, syöpäklinikkaryhmä.
authors.forename: Petri
authors.initials: P
authors.lastname: Bono
authors.forename: Heikki
authors.initials: H
authors.lastname: Joensuu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077341:Lapatinib; D011799:Quinazolines / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D000068878:Trastuzumab
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D011799:Quinazolines; D013629:Tamoxifen; D000077341:Lapatinib; D000068258:Bevacizumab; D000068878:Trastuzumab